- Home
- ABUS vs CEVA Comparison
ABUS vs CEVA Comparison
Compare ABUS & CEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CEVA
- Stock Information
- Founded
- ABUS 2005
- CEVA 1999
- Country
- ABUS United States
- CEVA United States
- Employees
- ABUS N/A
- CEVA N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CEVA Semiconductors
- Sector
- ABUS Health Care
- CEVA Technology
- Exchange
- ABUS Nasdaq
- CEVA Nasdaq
- Market Cap
- ABUS 611.0M
- CEVA 514.0M
- IPO Year
- ABUS N/A
- CEVA 2000
- Fundamental
- Price
- ABUS $3.37
- CEVA $23.31
- Analyst Decision
- ABUS Strong Buy
- CEVA Strong Buy
- Analyst Count
- ABUS 3
- CEVA 5
- Target Price
- ABUS $5.67
- CEVA $35.60
- AVG Volume (30 Days)
- ABUS 636.5K
- CEVA 266.4K
- Earning Date
- ABUS 08-06-2025
- CEVA 08-11-2025
- Dividend Yield
- ABUS N/A
- CEVA N/A
- EPS Growth
- ABUS N/A
- CEVA N/A
- EPS
- ABUS N/A
- CEVA N/A
- Revenue
- ABUS $15,416,000.00
- CEVA $106,353,000.00
- Revenue This Year
- ABUS $3.35
- CEVA $4.47
- Revenue Next Year
- ABUS N/A
- CEVA $16.50
- P/E Ratio
- ABUS N/A
- CEVA N/A
- Revenue Growth
- ABUS 53.23
- CEVA 7.71
- 52 Week Low
- ABUS $2.71
- CEVA $18.31
- 52 Week High
- ABUS $4.73
- CEVA $38.94
- Technical
- Relative Strength Index (RSI)
- ABUS 54.05
- CEVA 55.40
- Support Level
- ABUS $3.33
- CEVA $20.68
- Resistance Level
- ABUS $3.45
- CEVA $24.56
- Average True Range (ATR)
- ABUS 0.12
- CEVA 1.25
- MACD
- ABUS 0.01
- CEVA 0.19
- Stochastic Oscillator
- ABUS 36.21
- CEVA 69.88
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CEVA CEVA Inc.
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.